Developer docs
API playgroundTry for free, no card

Search company profiles

Clearmind Medicine

Full company profile

uuid0002abj

Namestring
Clearmind Medicine
Legal namestring
Clearmind Medicine Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Clearmind Medicine is a clinical-stage pharmaceutical biotech developing non-hallucinogenic, psychedelic-derived therapeutics based on its proprietary molecule MEAI (5-methoxy-2-aminoindane). The company's lead candidate, CMND-100, is an oral drug in FDA-regulated Phase I/IIa trials for Alcohol Use Disorder (AUD), with dosing completed across all 24 participants in 4 cohorts at Yale School of Medicine, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The company's mechanism targets 5-HT1A receptors to produce an alcohol-like euphoric experience while signaling satiety, positioning it as a 'binge-mitigating agent' that could address AUD, binge eating, gambling, and other impulse-control disorders.

Clearmind is pursuing an expanding indication strategy through preclinical programs combining MEAI with tirzepatide (with Yissum/Hebrew University) for obesity and metabolic dysfunction-associated steatotic liver disease, and with Palmitoylethanolamide (with NeuroThera Labs/SciSparc) for binge behavior and metabolic indications. The intellectual property portfolio comprises 32 granted patents across 19 patent families spanning the US, Europe, India, China, Hong Kong, Japan, South Korea, Mexico, and Australia, with additional filings in depression and PTSD. A February 2026 development agreement with Polyrizon extends the product surface into intranasal delivery.

The company is pre-revenue and headquartered in Vancouver, Canada with operational offices in Tel Aviv, Israel. It is publicly listed on NASDAQ (CMND), the Frankfurt Stock Exchange (CWY0), and the Canadian Securities Exchange (CMND), employs 11-50 staff, and is led by CEO Dr. Adi Zuloff-Shani. The revenue model is contingent on future FDA approval of CMND-100, after which Clearmind intends to commercialize via prescription drug sales targeting patients with AUD and other indications, and to monetize its patent estate through licensing agreements with larger pharmaceutical companies. Cumulative funding raised to date includes approximately $8.15M in equity offerings plus up to $10M in committed convertible-note financing, with market capitalization of roughly $2.5M as of May 2026 following two reverse stock splits.

Short descriptiontext

Clearmind Medicine is a clinical-stage biotech developing non-hallucinogenic, MEAI-based psychedelic therapeutics, led by CMND-100 for Alcohol Use Disorder in FDA Phase I/IIa trials, with pipeline expansion into obesity, depression, PTSD, and binge behavior disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic therapeutics, alcohol use disorder treatment, binge behavior regulation, neuroplastogen drug development, mental health pharmaceuticals
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Psychedelic Pharmaceuticals / Biotech Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech. Once CMND-100 receives regulatory approval (FDA), the company intends to commercialize its proprietary drug candidates as regulated medicines. Revenue would come from prescription drug sales targeting patients with Alcohol Use Disorder and other indications.

clearmindmedicine.com
2Licensing Royalties
TypeLicensing Royalties
Description

The company may pursue licensing agreements with larger pharmaceutical companies for the development and commercialization of its proprietary compounds and patent portfolio in various jurisdictions and therapeutic indications.

clearmindmedicine.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Clearmind Medicine is a clinical-stage biotech developing proprietary non-hallucinogenic psychedelic-derived therapeutics based on its novel molecule MEAI (5-methoxy-2-aminoindane). Its lead candidate CMND-100 is an oral drug for Alcohol Use Disorder currently in FDA-regulated Phase I/IIa clinical trials. The company also develops MEAI-based combination therapies for obesity, metabolic disorders, depression, PTSD, and binge behavior disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase I/IIa trial: All 24 participants across Cohorts 1-4 completed treatment with strong safety profile, no serious adverse events reported
+3 more records
Product overview1 text field

Clearmind Medicine is a clinical-stage neuroplastogens pharmaceutical biotech company developing non-hallucinogenic, second-generation psychedelic-derived therapeutics. The company's primary product portfolio centers on CMND-100, a proprietary oral drug candidate based on the MEAI (5-methoxy-2-aminoindane) molecule, which is being developed primarily for Alcohol Use Disorder (AUD) treatment. The MEAI molecule acts as a 'binge-mitigating agent' that produces alcohol-like euphoria while signaling the brain that it is satisfied, reducing the desire to consume alcohol. CMND-100 is currently undergoing Phase I/IIa FDA-regulated clinical trials at leading institutions. The company is also exploring additional therapeutic applications of MEAI including depression, obesity/metabolic disorders, PTSD, and cocaine addiction. Clearmind's intellectual property portfolio consists of 19 patent families with 32 granted patents across multiple jurisdictions worldwide.

Product and service2 records
1CMND-100
CategoryCore product
Description

Proprietary non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). Currently in Phase I/IIa FDA-regulated clinical trials at leading institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Demonstrated strong safety profile with no serious adverse events reported across all 24 participants in Part A.

2MEAI (5-methoxy-2-aminoindane)
CategoryCore product / Active pharmaceutical ingredient
Description

Proprietary psychoactive aminoindane molecule that exerts a euphoric alcohol-like experience and reduces desire to consume alcoholic beverages. Acts on neural pathways including 5-HT1A to decrease impulsivity. Active ingredient in CMND-100, being developed for multiple indications including AUD, depression, obesity, and binge behaviors.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

12-month preclinical research agreement evaluating MEAI (CMND-100) in combination with tirzepatide and as maintenance therapy following tirzepatide treatment in diet-induced obese mice. Study conducted by Professor Joseph Tam's team at Hebrew University. Builds on prior research showing MEAI achieved approximately 15-20% body weight reduction through increased energy expenditure while preserving lean mass.

2NeuroThera Labs Inc. (Subsidiary of SciSparc Ltd.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Collaboration on combination therapy of MEAI with Palmitoylethanolamide (PEA) targeting obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and binge behavior disorders. Collaboration has resulted in 13 patent families across multiple jurisdictions. MEAI provides neuroplastic properties while PEA offers anti-inflammatory and neuroprotective benefits.

biospace.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-06
Description

Development agreement to create an intranasal formulation of MEAI using Polyrizon's proprietary intranasal hydrogel technology. The partnership aims to improve bioavailability through enhanced nasal residence time and targeted delivery for CNS-targeted compounds. Classified as a related party transaction under Canadian securities regulations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Study led by Dr. David Zeltser, Director of Emergency Medicine Department. One of the leading clinical sites in Israel participating in the multinational trial.

5Hadassah-University Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Led by Prof. Yossi Karko, Director of Center for Clinical Research, and Prof. Joseph Caraco, Director of Clinical Pharmacology Unit. One of the premier research institutions in Israel.

clearmindmedicine.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading U.S. clinical trial site for Phase I/IIa trial of CMND-100. Department of Psychiatry involvement in the FDA-regulated multicenter, randomized, double-blind, placebo-controlled study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading U.S. clinical trial site for Phase I/IIa trial of CMND-100. Johns Hopkins Medicine Institutional Review Board approved advancement to Parts B and C of the trial. Key site for safety and tolerability evaluation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Commercial and clinical-stage CNS-focused biopharmaceutical company with a broader neurology and psychiatry portfolio (e.g., fibromyalgia, migraine). Overlaps with Clearmind's CNS specialty pharmaceutical focus but operates across a wider set of indications.

TypeDirect peer
Description

Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analog CYB003 for depression and other mental health conditions. Comparable in size, stage, and psychedelic CNS focus.

TypeDirect peer
Description

Late-stage psychedelic biotech developing psilocybin therapy for treatment-resistant depression. Comparable to Clearmind as a publicly-traded, FDA-regulated psychedelic therapeutics company pursuing CNS indications with proprietary novel molecules.

TypeDirect peer
Description

Clinical-stage company developing mebufotenin and other psychedelic-derived candidates for treatment-resistant depression. Comparable to Clearmind as a small-cap, FDA-regulated psychedelic therapeutics developer focused on CNS indications.

5atai Life Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical platform developing psychedelic and non-psychedelic therapeutics for mental health, including depression and addiction. Closely comparable to Clearmind in psychedelic-derived CNS pipeline strategy.

6MindMed
TypeDirect peer
Description

Clinical-stage psychedelic medicine biotech developing candidates for anxiety, ADHD, and substance use disorders. Directly comparable to Clearmind as a public, CNS-focused psychedelic-derived therapeutics developer with overlapping addiction indications.

TypeBroad incumbent
Description

Commercial-stage CNS biopharmaceutical company with FDA-approved Auvelity for major depressive disorder and others for migraine. Comparable as a publicly-traded CNS specialty pharma pursuing novel mechanisms in psychiatry.

8NeuroThera Labs (SciSparc)
TypeEmerging player
Description

Specialty pharmaceutical company developing cannabinoid-based therapies for CNS indications, including a collaboration with Clearmind on MEAI+PEA combinations. Directly involved as a partner and represents a peer in CNS combination therapeutics.

TypeBroad incumbent
Description

Established CNS biopharmaceutical company with FDA-approved Zurzuvae for postpartum depression and a pipeline targeting depression and neurological disorders. A broader incumbent in the CNS specialty pharmaceutical category where Clearmind also operates.

10Bionomics Limited
TypeEmerging player
Description

Clinical-stage CNS biopharmaceutical company developing BNC210 for anxiety and PTSD. Comparable as a small-cap CNS-focused emerging player targeting overlapping mental health indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clearmind Medicine

Psychedelic Pharmaceuticals / Biotech Therapeuticsclearmindmedicine.com

Clearmind Medicine is a clinical-stage biotech developing non-hallucinogenic, MEAI-based psychedelic therapeutics, led by CMND-100 for Alcohol Use Disorder in FDA Phase I/IIa trials, with pipeline expansion into obesity, depression, PTSD, and binge behavior disorders.

What Clearmind Medicine does

Clearmind Medicine is a clinical-stage pharmaceutical biotech developing non-hallucinogenic, psychedelic-derived therapeutics based on its proprietary molecule MEAI (5-methoxy-2-aminoindane). The company's lead candidate, CMND-100, is an oral drug in FDA-regulated Phase I/IIa trials for Alcohol Use Disorder (AUD), with dosing completed across all 24 participants in 4 cohorts at Yale School of Medicine, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The company's mechanism targets 5-HT1A receptors to produce an alcohol-like euphoric experience while signaling satiety, positioning it as a 'binge-mitigating agent' that could address AUD, binge eating, gambling, and other impulse-control disorders.

Clearmind is pursuing an expanding indication strategy through preclinical programs combining MEAI with tirzepatide (with Yissum/Hebrew University) for obesity and metabolic dysfunction-associated steatotic liver disease, and with Palmitoylethanolamide (with NeuroThera Labs/SciSparc) for binge behavior and metabolic indications. The intellectual property portfolio comprises 32 granted patents across 19 patent families spanning the US, Europe, India, China, Hong Kong, Japan, South Korea, Mexico, and Australia, with additional filings in depression and PTSD. A February 2026 development agreement with Polyrizon extends the product surface into intranasal delivery.

The company is pre-revenue and headquartered in Vancouver, Canada with operational offices in Tel Aviv, Israel. It is publicly listed on NASDAQ (CMND), the Frankfurt Stock Exchange (CWY0), and the Canadian Securities Exchange (CMND), employs 11-50 staff, and is led by CEO Dr. Adi Zuloff-Shani. The revenue model is contingent on future FDA approval of CMND-100, after which Clearmind intends to commercialize via prescription drug sales targeting patients with AUD and other indications, and to monetize its patent estate through licensing agreements with larger pharmaceutical companies. Cumulative funding raised to date includes approximately $8.15M in equity offerings plus up to $10M in committed convertible-note financing, with market capitalization of roughly $2.5M as of May 2026 following two reverse stock splits.

Clearmind Medicine firmographics

Firmographics
Name
Clearmind Medicine
Legal name
Clearmind Medicine Inc.
Website
https://clearmindmedicine.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Clearmind Medicine is a clinical-stage biotech developing non-hallucinogenic, MEAI-based psychedelic therapeutics, led by CMND-100 for Alcohol Use Disorder in FDA Phase I/IIa trials, with pipeline expansion into obesity, depression, PTSD, and binge behavior disorders.
Ownership category
akta.pro rank

Clearmind Medicine industry classification

Industry
Product category
Psychedelic Pharmaceuticals / Biotech Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Psychedelic therapeutics
  • Alcohol use disorder treatment
  • Binge behavior regulation
  • Neuroplastogen drug development
  • Mental health pharmaceuticals

Where Clearmind Medicine is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Clearmind Medicine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech. Once CMND-100 receives regulatory approval (FDA), the company intends to commercialize its proprietary drug candidates as regulated medicines. Revenue would come from prescription drug sales targeting patients with Alcohol Use Disorder and other indications.
  2. Licensing Royalties: The company may pursue licensing agreements with larger pharmaceutical companies for the development and commercialization of its proprietary compounds and patent portfolio in various jurisdictions and therapeutic indications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Clearmind Medicine product offering

Product offering

Core offering

Clearmind Medicine is a clinical-stage biotech developing proprietary non-hallucinogenic psychedelic-derived therapeutics based on its novel molecule MEAI (5-methoxy-2-aminoindane). Its lead candidate CMND-100 is an oral drug for Alcohol Use Disorder currently in FDA-regulated Phase I/IIa clinical trials. The company also develops MEAI-based combination therapies for obesity, metabolic disorders, depression, PTSD, and binge behavior disorders.

Product overview

Clearmind Medicine is a clinical-stage neuroplastogens pharmaceutical biotech company developing non-hallucinogenic, second-generation psychedelic-derived therapeutics. The company's primary product portfolio centers on CMND-100, a proprietary oral drug candidate based on the MEAI (5-methoxy-2-aminoindane) molecule, which is being developed primarily for Alcohol Use Disorder (AUD) treatment. The MEAI molecule acts as a 'binge-mitigating agent' that produces alcohol-like euphoria while signaling the brain that it is satisfied, reducing the desire to consume alcohol. CMND-100 is currently undergoing Phase I/IIa FDA-regulated clinical trials at leading institutions. The company is also exploring additional therapeutic applications of MEAI including depression, obesity/metabolic disorders, PTSD, and cocaine addiction. Clearmind's intellectual property portfolio consists of 19 patent families with 32 granted patents across multiple jurisdictions worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • CMND-100 Proprietary non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). Currently in Phase I/IIa FDA-regulated clinical trials at leading institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Demonstrated strong safety profile with no serious adverse events reported across all 24 participants in Part A.
  • MEAI (5-methoxy-2-aminoindane) Proprietary psychoactive aminoindane molecule that exerts a euphoric alcohol-like experience and reduces desire to consume alcoholic beverages. Acts on neural pathways including 5-HT1A to decrease impulsivity. Active ingredient in CMND-100, being developed for multiple indications including AUD, depression, obesity, and binge behaviors.

Quantifiable outcome

  • Phase I/IIa trial: All 24 participants across Cohorts 1-4 completed treatment with strong safety profile, no serious adverse events reported
  • +3 more outcomes

Companies that use Clearmind Medicine

Customer profile

Segments5 records

Ideal customer profiles3 records

Clearmind Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Clearmind Medicine partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Yissum Research Development Company of Hebrew University of JerusalemcoreStrategic or Co-development Partner · 18 May 202612-month preclinical research agreement evaluating MEAI (CMND-100) in combination with tirzepatide and as maintenance therapy following tirzepatide treatment in diet-induced obese mice. Study conducted by Professor Joseph Tam's team at Hebrew University. Builds on prior research showing MEAI achieved approximately 15-20% body weight reduction through increased energy expenditure while preserving lean mass.
  • NeuroThera Labs Inc. (Subsidiary of SciSparc Ltd.)coreStrategic or Co-development Partner · 10 March 2026Collaboration on combination therapy of MEAI with Palmitoylethanolamide (PEA) targeting obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and binge behavior disorders. Collaboration has resulted in 13 patent families across multiple jurisdictions. MEAI provides neuroplastic properties while PEA offers anti-inflammatory and neuroprotective benefits.
  • Polyrizon Ltd.coreTechnology or Integration · 6 February 2026Development agreement to create an intranasal formulation of MEAI using Polyrizon's proprietary intranasal hydrogel technology. The partnership aims to improve bioavailability through enhanced nasal residence time and targeted delivery for CNS-targeted compounds. Classified as a related party transaction under Canadian securities regulations.
  • Tel Aviv Sourasky Medical Center (TASMC)coreStrategic or Co-development PartnerClinical trial site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Study led by Dr. David Zeltser, Director of Emergency Medicine Department. One of the leading clinical sites in Israel participating in the multinational trial.
  • Hadassah-University Medical CentercoreStrategic or Co-development PartnerClinical trial site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. Led by Prof. Yossi Karko, Director of Center for Clinical Research, and Prof. Joseph Caraco, Director of Clinical Pharmacology Unit. One of the premier research institutions in Israel.
  • Yale School of MedicinecoreStrategic or Co-development PartnerLeading U.S. clinical trial site for Phase I/IIa trial of CMND-100. Department of Psychiatry involvement in the FDA-regulated multicenter, randomized, double-blind, placebo-controlled study.
  • Johns Hopkins University School of MedicinecoreStrategic or Co-development PartnerLeading U.S. clinical trial site for Phase I/IIa trial of CMND-100. Johns Hopkins Medicine Institutional Review Board approved advancement to Parts B and C of the trial. Key site for safety and tolerability evaluation.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Clearmind Medicine competitors and assessment

Company assessment

Broad incumbents

  • Tonix Pharmaceuticals: Commercial and clinical-stage CNS-focused biopharmaceutical company with a broader neurology and psychiatry portfolio (e.g., fibromyalgia, migraine). Overlaps with Clearmind's CNS specialty pharmaceutical focus but operates across a wider set of indications.
  • Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company with FDA-approved Auvelity for major depressive disorder and others for migraine. Comparable as a publicly-traded CNS specialty pharma pursuing novel mechanisms in psychiatry.
  • Sage Therapeutics: Established CNS biopharmaceutical company with FDA-approved Zurzuvae for postpartum depression and a pipeline targeting depression and neurological disorders. A broader incumbent in the CNS specialty pharmaceutical category where Clearmind also operates.

Direct peers

  • Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analog CYB003 for depression and other mental health conditions. Comparable in size, stage, and psychedelic CNS focus.
  • Compass Pathways: Late-stage psychedelic biotech developing psilocybin therapy for treatment-resistant depression. Comparable to Clearmind as a publicly-traded, FDA-regulated psychedelic therapeutics company pursuing CNS indications with proprietary novel molecules.
  • GH Research: Clinical-stage company developing mebufotenin and other psychedelic-derived candidates for treatment-resistant depression. Comparable to Clearmind as a small-cap, FDA-regulated psychedelic therapeutics developer focused on CNS indications.
  • atai Life Sciences: Clinical-stage biopharmaceutical platform developing psychedelic and non-psychedelic therapeutics for mental health, including depression and addiction. Closely comparable to Clearmind in psychedelic-derived CNS pipeline strategy.
  • MindMed: Clinical-stage psychedelic medicine biotech developing candidates for anxiety, ADHD, and substance use disorders. Directly comparable to Clearmind as a public, CNS-focused psychedelic-derived therapeutics developer with overlapping addiction indications.

Emerging players

  • NeuroThera Labs (SciSparc): Specialty pharmaceutical company developing cannabinoid-based therapies for CNS indications, including a collaboration with Clearmind on MEAI+PEA combinations. Directly involved as a partner and represents a peer in CNS combination therapeutics.
  • Bionomics Limited: Clinical-stage CNS biopharmaceutical company developing BNC210 for anxiety and PTSD. Comparable as a small-cap CNS-focused emerging player targeting overlapping mental health indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Clearmind Medicine social profiles

Digital presence

Clearmind Medicine compliance and trust

Trust signal

Compliance1 record

Clearmind Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clearmind Medicine leadership team

Management profile

Number of profiles

Profiles12 records

Clearmind Medicine funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clearmind Medicine M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clearmind Medicine

What does Clearmind Medicine do?

Clearmind Medicine is a clinical-stage biotech developing proprietary non-hallucinogenic psychedelic-derived therapeutics based on its novel molecule MEAI (5-methoxy-2-aminoindane). Its lead candidate CMND-100 is an oral drug for Alcohol Use Disorder currently in FDA-regulated Phase I/IIa clinical trials. The company also develops MEAI-based combination therapies for obesity, metabolic disorders, depression, PTSD, and binge behavior disorders.

Is Clearmind Medicine a public or private company?

Clearmind Medicine is a public company. It is classified as public and is currently operating.

When was Clearmind Medicine founded?

Clearmind Medicine was founded in 2015. It employs 1 to 10 people.

Where is Clearmind Medicine based?

Clearmind Medicine is headquartered in Vancouver, Canada, in the North America region.

How does Clearmind Medicine make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties.

Who are Clearmind Medicine's main competitors?

Broad incumbents on record are Tonix Pharmaceuticals, Axsome Therapeutics and Sage Therapeutics. Direct peers are Cybin, Compass Pathways, GH Research, atai Life Sciences and MindMed. Emerging players are NeuroThera Labs (SciSparc) and Bionomics Limited.

Does Clearmind Medicine have an API?

No public API is recorded for Clearmind Medicine.

What industry is Clearmind Medicine in?

Clearmind Medicine's product category is Psychedelic Pharmaceuticals / Biotech Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comClearmind completes enrollment for CMND-100 trial part CClearmind Medicine completed enrollment for Part C of its Phase I/IIa trial of CMND-100, a randomized, double-blind, placebo-controlled multiple-dose study. The trial assesses safety, tolerability, and pharmacokinetics at sites in the US and Israel, including Johns Hopkins and Yale. The company previously enrolled the first cohort in Part B for patients with moderate-to-severe alcohol use disorder.Quiver QuantitativeClearmind Medicine Invited to BrainFutures Frontiers of Mental Health and Recovery Summit in Washington, D.C. | CMND Stock NewsClearmind Medicine was invited to the Frontiers of Mental Health and Recovery Summit in Washington D.C., where its Chief of Global Impact will present insights on CMND-100, an investigational treatment for Alcohol Use Disorder. The company aims to develop psychedelic-derived neuroplastogens as regulated therapies and advocate for patient access through existing healthcare resources.GlobeNewswireClearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic SummitClearmind Medicine announced it will join the Frontiers of Mental Health and Recovery Summit in Washington D.C., with Chief of Global Impact Mary-Elizabeth Gifford invited to participate. She will share insights on CMND-100, its investigational neuroplastogen for Alcohol Use Disorder, and updates from Phase II trials at Yale and Johns Hopkins. The summit aims to accelerate system readiness for psychedelic therapies.FinancialContent Business PageClearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic SummitClearmind Medicine announced it will join a Washington DC summit on psychedelic therapies, with its Chief of Global Impact invited to participate. The company will share insights on its CMND-100 candidate for Alcohol Use Disorder and updates from Phase II trials at Yale and Johns Hopkins. The summit aims to accelerate system readiness for psychedelic treatments.Stock TitanClearmind invited to Washington psychedelic summitClearmind Medicine was invited to the Frontiers of Mental Health and Recovery Summit in Washington, D.C., where it will discuss its psychedelic-derived neuroplastogen approach. The company will present updates on its Phase II trials and CMND-100, a candidate for alcohol use disorder, aiming to reduce supervised dosing.Business & FinancialClearmind Successfully Completes Patient Recruitment For The First Alcohol Use Disorder Cohort Of Its CMND-100 Phase I/Iia Clinical TrialClearmind Medicine completed patient recruitment for the first segment of Part B of its Phase I/IIa trial of CMND-100 in moderate-to-severe alcohol use disorder. The trial includes two ascending-dose cohorts (80 mg and 160 mg) with six patients each, assessing safety, tolerability, pharmacokinetics, and early efficacy signals. The company aims to generate the first dedicated clinical dataset for AUD.Quiver QuantitativeClearmind Medicine Completes Recruitment for First Part B Cohort in Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock NewsClearmind Medicine completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for alcohol use disorder. The trial assesses safety, tolerability, pharmacokinetics, and early efficacy, including alcohol craving reduction, at U.S. and Israeli sites. The company aims to generate dedicated clinical data for the AUD population.Investing.comClearmind completes patient recruitment for AUD trial segmentClearmind Medicine completed patient recruitment for the first segment of Part B of its Phase I/IIa trial of CMND-100 in moderate-to-severe alcohol use disorder. The segment includes two single-dose ascending cohorts at 80 mg and 160 mg, each with six patients, to assess safety, tolerability, pharmacokinetics, and early efficacy signals.TradingViewClearmind Medicine Inc. (CMND) Completes Recruitment for First AUD Cohort in CMND-100 TrialClearmind Medicine completed recruitment for the first Part B single-dose cohort in its Phase I/IIa CMND-100 trial for moderate-to-severe alcohol use disorder. The trial now tests safety, pharmacokinetics, tolerability, and early efficacy signals in AUD patients, with two cohorts at 80mg and 160mg.Ticker ReportClearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Report for SeptemberClearmind Medicine's short interest fell 58.5% to 14,819 shares as of September 30th, with 11.4% of shares short sold. The stock rose 1.8% to $6.41, while analysts set new price targets, including Zen's upgrade to a sell rating.